Inventorying geological heritage in large territories : a methodological proposal applied to Brazil

An adequate management of geological heritage by national and regional authorities presupposes the existence of a solid geosites inventory. Unfortunately, this is not the case for many countries. Most often, there is no national inventory at all or the method and criteria used to assess geosites was not adequate. This paper makes an overview of the strengths and weaknesses of the most common procedures to produce a geosite inventory and proposes a methodology particularly adapted for large territories such as Brazil. Nevertheless, this methodological approach can be easily adapted to any other geographical or geological setting, promoting the characterization and conservation of the world's geological heritage.High Level Scholarship Programme of the European Union - Programme AlβanFundação para a Ciência e a Tecnologia (FCT)

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies.In mantle cell lymphoma (JeKo-1), Burkitt's lymphoma (Raji), and acute lymphoblastic leukemia (697) cell lines, the 48-hr IC(50) (50% growth inhibitory concentration) of AR-42 is 0.61 microM or less. In chronic lymphocytic leukemia (CLL) patient cells, the 48-hr LC(50) (concentration lethal to 50%) of AR-42 is 0.76 microM. AR-42 produces dose- and time-dependent acetylation both of histones and tubulin, and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells. AR-42 also sensitizes CLL cells to TNF-Related Apoptosis Inducing Ligand (TRAIL), potentially through reduction of c-FLIP. AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity.Together, these data demonstrate that AR-42 has in vitro and in vivo efficacy at tolerable doses. These results strongly support upcoming phase I testing of AR-42 in B-cell malignancies